BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2002/12/231 分で読めます

SoloPak Laboratories, Inc.; Withdrawal of Approval of 1 New Drug Application and 38 Abbreviated New Drug Applications; Correction

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 21, 1999 (64 FR 33097; corrected July 19, 1999 (64 FR 38675)). The document, which announced the withdrawal of approval of 1 new drug application (NDA) and 38 abbeviated new drug applications held by SoloPak Laboratories, Inc., inadvertently withdrew approval of NDA 19-961 for Ganite (gallium nitrate). FDA has subsequently learned that SoloPak, at the time it requested withdrawal of this NDA, was not its holder. Therefore, SoloPak was not authorized to make such a request. FDA confirms that approval of NDA 19-961, currently held by Genta, Inc., is still in effect.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

関連インサイト

ビジネスインサイト →